Skip to main content

Table 4 Patient background

From: Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson’s disease

Male: Female 14:13  
Age (years) 72.3 ± 9.2 (range 47–84)
Education (years) 12.2 ± 3.2 (range 3–16)
Duration from symptom onset (years) 1.3 ± 1.2  
  (<  1 year 7 persons)
  (≥ 1, <  2 years 12 persons)
  (≥ 2, <  3 years 4 persons)
  (≥ 3, <  4 years 3 persons)
  (≥ 4, <  5 years 0 person)
  (≥ 5, <  6 years 1 person)
Clinical assessment scores
UPDRS
 Part III (motor score) 16.7 ± 8.2 (range 5–31)
 Tremor 2.6 ± 2.6 (range 0–10)
 Rigidity 3.0 ± 2.3 (range 0–10)
 Bradykinesia 6.4 ± 4.4 (range 0–16)
 Gait 2.5 ± 2.0 (range 0–7)
 Postural instability 2.4 ± 1.9 (range 0–6)
 MoCA 21.7 ± 5.5 (range 9–28)
COGNISTAT
 Orientation 8.9 ± 1.3 (range 6–10)
 Attention 6.3 ± 3.8 (range 1–10)
 Language-comprehension 8.7 ± 2.9 (range 1–10)
 Language-repetition 8.6 ± 2.3 (range 4–11)
 Language-naming 9.0 ± 1.6 (range 5–10)
Construction 7.5 ± 1.8 (range 4–11)
 Memory 7.5 ± 1.7 (range 5–10)
 Calculation 8.6 ± 2.5 (range 2–10)
 Similarity 9.1 ± 1.2 (range 6–11)
 Judgement 9.8 ± 1.3 (range 7–12)
CSF protein levels
 Total αS (pg/ml) 1517.3 ± 654.3 (range 573–3387)
 O-αS (RLU/s) 107,019.5 ± 20,203.1 (range 74,867–161,685)
 Aβ1–42 (pg/ml) 427.1 ± 159.7 (range 206.4–724.5)
 Total tau (pg/ml) 38.4 ± 21.2 (range 11.2–93.9)
 P-tau181p (pg/ml) 15.3 ± 6.1 (range 5.8–29.9)
  1. Scores are shown as Mean ± Standard Deviation. Abbreviations: UPDRS, Unified Parkinson’s Disease Rating Scale; MoCA, the Montreal Cognitive Assessment; COGNISTAT, the Neurobehavioral Cognitive Status Examination; Total αS, Total α-synuclein; O-αS, Oligomeric α-synuclein; P-Tau181p, tau phosphorylated at threonine 181